Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) shares saw an uptick in trading volume on Wednesday . 32,512 shares were traded during mid-day trading, a decline of 95% from the previous session's volume of 637,692 shares.The stock last traded at $24.20 and had previously closed at $26.45.
Analysts Set New Price Targets
A number of brokerages recently weighed in on ZNTL. SVB Leerink reduced their target price on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an "outperform" rating on the stock in a report on Wednesday, August 10th. Morgan Stanley reduced their target price on Zentalis Pharmaceuticals from $95.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, August 11th. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Finally, Guggenheim cut their price objective on Zentalis Pharmaceuticals to $57.00 and set a "na" rating on the stock in a research report on Tuesday, May 17th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $61.38.
Get Zentalis Pharmaceuticals alerts:Zentalis Pharmaceuticals Price Performance
The firm has a market capitalization of $1.37 billion, a PE ratio of -6.87 and a beta of 1.88. The stock has a 50-day moving average price of $28.58 and a 200-day moving average price of $30.83.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.21) by ($0.13). As a group, equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -4.78 earnings per share for the current fiscal year.Insider Activity at Zentalis Pharmaceuticals
In related news, COO Kevin D. Bunker sold 1,710 shares of the business's stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the sale, the chief operating officer now directly owns 108,290 shares of the company's stock, valued at $3,250,865.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Zentalis Pharmaceuticals news, COO Kevin D. Bunker sold 5,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the chief operating officer now directly owns 100,000 shares in the company, valued at $3,000,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Kevin D. Bunker sold 1,710 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the transaction, the chief operating officer now owns 108,290 shares of the company's stock, valued at $3,250,865.80. The disclosure for this sale can be found here. Insiders sold a total of 31,710 shares of company stock valued at $953,084 over the last three months. 19.90% of the stock is owned by insiders.
Hedge Funds Weigh In On Zentalis Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Matrix Capital Management Company LP boosted its stake in Zentalis Pharmaceuticals by 111.5% in the second quarter. Matrix Capital Management Company LP now owns 9,199,973 shares of the company's stock valued at $258,519,000 after acquiring an additional 4,850,694 shares during the period. Decheng Capital Management III Cayman LLC acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $51,271,000. State Street Corp lifted its position in Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company's stock worth $87,665,000 after purchasing an additional 1,039,294 shares during the period. FMR LLC lifted its position in Zentalis Pharmaceuticals by 15.3% in the second quarter. FMR LLC now owns 7,776,168 shares of the company's stock worth $218,510,000 after purchasing an additional 1,033,474 shares during the period. Finally, Perceptive Advisors LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter worth approximately $36,192,000.
About Zentalis Pharmaceuticals
(Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Featured Articles
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- Is Five Below Trying to Punch Too High?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.